 |
|
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase II | Treatment | Active | 18 and over | A4061027
NCT00389441 |
Trial Description
Summary The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine Eligibility Criteria Inclusion Criteria: - Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer
- At least 1 measurable target lesion, as defined by RECIST
Exclusion Criteria: - Previous treatment with anti-angiogenesis agents
- No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.
Trial Contact Information
Trial Lead Organizations/Sponsors Pfizer Incorporated | Pfizer CT.gov Call Center | | Study Director |
| Pfizer CT.gov Call Center | | Ph: 1-800-718-1021 |
Trial Sites
|
|
|
|
| U.S.A. |
|
| California |
|
| |
Orange |
|
| | | | | | | | Pfizer Investigational Site |
|
| Italy |
|
| |
Milano |
|
| | | | Pfizer Investigational Site |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00389441
Information obtained from ClinicalTrials.gov on April 28, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
